# AZD3470

Source: https://onco.cc/drugs/azd3470/  
OnCo record `azd3470` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD3470 is an experimental small-molecule drug from AstraZeneca in phase 2 trials for hodgkin lymphoma and peripheral T-cell lymphomas, aimed at PRMT5 (MTAP-deleted cancers).

## Summary

AZD3470 is a small-molecule drug developed by AstraZeneca. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: AZD3470 is a second-generation, MTAP-selective, MTA-cooperative inhibitor of PRMT5, designed for tumours with MTAP deletion/deficiency. ClinicalTrials.gov describes the intervention as: AZD3470 is a novel, potent and selective, second-generation, MTAP-selective, inhibitor of PRMT5. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in hodgkin lymphoma and peripheral T-cell lymphomas. The largest, NCT06130553, plans to enrol 334 participants with primary completion expected 2028-12-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: AZD3470 is a second-generation, MTAP-selective, MTA-cooperative inhibitor of PRMT5, designed for tumours with MTAP deletion/deficiency.

## Sources

- ClinicalTrials.gov: trials of AZD3470: https://clinicaltrials.gov/search?intr=AZD3470

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/)
- targets: [PRMT5 (MTAP-deleted cancers)](https://onco.cc/targets/prmt5-mtap/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06130553/), [AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.](https://onco.cc/trials/nct06137144/)

---
JSON: https://onco.cc/api/v1/entities/azd3470.json